| Literature DB >> 26180786 |
Yongjie Xu1, Chuanjun Zhuo2, Wen Qin1, Jiajia Zhu1, Chunshui Yu1.
Abstract
Altered spontaneous brain activity as measured by ALFF, fALFF, and ReHo has been reported in schizophrenia, but no consensus has been reached on alternations of these indexes in the disorder. We aimed to clarify the regional alterations in ALFF, fALFF, and ReHo in schizophrenia using a meta-analysis and a large-sample validation. A meta-analysis of activation likelihood estimation was conducted based on the abnormal foci of ten studies. A large sample of 86 schizophrenia patients and 89 healthy controls was compared to verify the results of the meta-analysis. Meta-analysis demonstrated that the alternations in ALFF and ReHo had similar distribution in schizophrenia patients. The foci with decreased ALFF/fALFF and ReHo in schizophrenia were mainly located in the somatosensory cortex, posterior parietal cortex, and occipital cortex; however, foci with increased ALFF/fALFF and ReHo were mainly located in the bilateral striatum, medial temporal cortex, and medial prefrontal cortex. The large-sample study showed consistent findings with the meta-analysis. These findings may expound the pathophysiological hypothesis and guide future research.Entities:
Mesh:
Year: 2015 PMID: 26180786 PMCID: PMC4477065 DOI: 10.1155/2015/204628
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The demographic and clinical data of studies included in the meta-analysis.
| References | Publication year | Scanners | Indices | Patients | Controls | Patients | Controls | Diagnosis | Duration of illness | PANSS total | PANSS positive | PANSS negative |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoptman et al. [ | 2010 | Siemens 1.5T | ALFF/fALFF | 36.5 ± 11.0 | 41.9 ± 10.9 | 29/3 | 26/7 | CS | 13.0 ± 7.2 (years) | 76.5 ± 16.6 | 18.4 ± 6.2 | 20.2 ± 6.2 |
| Huang et al. [ | 2010 | GE 3T | ALFF | 24.2 ± 8.4 | 24.5 ± 8.6 | 66/36 | 66/36 | FES | 8.8 ± 14.1 (months) | 107.2 ± 15.1 | 26.4 ± 5.2 | 20.7 ± 6.3 |
| He et al. [ | 2013 | GE 3T | fALFF | 25.4 ± 8.3 | 26.6 ± 8.9 | 104/55 | 104/54 | FES | 39.5 ± 31.9 (weeks) | 92.1 ± 17.5 | — | — |
| Ren et al. [ | 2013 | GE 3T | ALFF | 24.3 ± 7.5 | 24.4 ± 7.6 | 100/59 | 100/59 | FES | 6.3 ± 11.0 (months) | 97.9 ± 17.8 | 25.1 ± 6.0 | 18.8 ± 7.7 |
| Turner et al. [ | 2013 | Siemens/GE 3T | ALFF/fALFF | 34.4–44.8 | 34.4–42.5 | 146/35 | 160/46 | CS | 13.1–24.1 (years) | 53.8–64.7 | 13.5–16.5 | 13.1–16.7 |
| Yu et al. [ | 2014 | Siemens 3T | ALFF/fALFF | 31.7 ± 9.6 | 29.9 ± 8.6 | 69/35 | 62/27 | CS | 7.1 ± 6.5 (years) | 52.9 ± 16.8 | 12.1 ± 4.7 | 13.4 ± 6.1 |
| Liu et al. [ | 2006 | GE 1.5T | ReHo | 23.7 ± 4.4 | 24.4 ± 3.9 | 18/9 | 18/9 | Mixed | 26.8 ± 19.2 (months) | 80.4 ± 18.7 | — | — |
| Jiang et al. [ | 2010 | GE 1.5T | ReHo | 16.4 ± 0.8 | 16.3 ± 0.9 | 18/9 | 18/9 | EOS | 9.6 ± 5.9 (months) | 91.8 ± 6.7 | — | — |
| Chen et al. [ | 2013 | Siemens 3T | ReHo | 28.3 ± 1.43 | 35.7 ± 1.8 | 36/20 | 44/27 | FES | — | 25.2 ± 6.9 | — | — |
| Yu et al. [ | 2013 | Siemens 3T | ReHo | 31.7 ± 9.6 | 29.9 ± 8.6 | 69/36 | 62/27 | CS | 7.1 ± 6.5 (years) | 52.9 ± 16.8 | 12.1 ± 4.7 | 13.4 ± 6.1 |
Turner et al. [17] present the demographic information in 7 sites, respectively. Thus we only show the ranges of mean values from the 7 sites.
All studies did not give the medication information except for the study of Hoptman et al. [13], so we did not list the information in the table.
F, female; PANSS, Positive and Negative Syndrome Scale; FES, first-episode schizophrenia; CS, chronic schizophrenia; Mixed, FES and CS; EOS, early onset schizophrenia.
Detailed area of studies included in the meta-analysis.
| Regions | ALFF | fALFF | ReHo | |||
|---|---|---|---|---|---|---|
| Increase | Decrease | Increase | Decrease | Increase | Decrease | |
| L-MPFC | [ | [ | [ | |||
| R-MPFC | [ | [ | [ | [ | ||
| OFC | [ | [ | [ | [ | [ | |
| R-PCL | [ | [ | ||||
| L-post_CG | [ | |||||
| R-post_CG | [ | [ | ||||
| L-preCG | [ | [ | [ | |||
| R-preCG | [ | [ | [ | |||
| L-STG | [ | [ | ||||
| R-STG | [ | [ | ||||
| L-MTG | [ | [ | ||||
| R-MTG | [ | [ | ||||
| L-ITG | [ | [ | ||||
| R-ITG | [ | |||||
| L-HG | [ | [ | ||||
| L-PH | [ | [ | ||||
| R-PH | [ | [ | ||||
| L-Fus | [ | [ | ||||
| L-HP | [ | [ | ||||
| L-aINS | [ | [ | [ | |||
| R-aINS | [ | [ | [ | |||
| L-pINS | [ | [ | [ | [ | ||
| L-MOG | [ | [ | [ | |||
| R-MOG | [ | [ | [ | [ | ||
| L-IOG | [ | [ | ||||
| R-IOG | [ | [ | ||||
| L-Cun | [ | [ | ||||
| R-Cun | [ | [ | ||||
| L-LG | [ | |||||
| R-LG | [ | [ | ||||
| R-Cal | [ | |||||
| L-Cau | [ | |||||
| R-Cau | [ | |||||
| L-Put | [ | [ | ||||
| R-Put | [ | [ | ||||
| L-HTh | [ | |||||
| L-Cla | [ | |||||
| R-LN | [ | |||||
| L-ACC | [ | |||||
| R-PCC | [ | [ | ||||
| R-SPL | [ | |||||
| L-IPL | [ | [ | [ | |||
| R-IPL | [ | |||||
| L-Pcu | [ | |||||
| R-Pcu | [ | [ | [ | |||
L, left; R, right; MPFC, medial prefrontal cortex; PCL, paracentral lobule; post_CG, postcentral gyrus; preCG, precentral gyrus; STG, superior temporal gyrus; MTG, middle temporal gyrus; ITG, inferior temporal gyrus; HG, Heschl gyrus; PH, parahippocampal; Fus, fusiform; HP, hippocampus; aINS, anterior insula; pINS, posterior insula; MOG, middle occipital gyrus; IOG, inferior occipital gyrus; Cun, cuneus; LG, lingual gyrus; Cal, calcarine; Cau, caudate; Put, putamen; HTh, hypothalamus; Cla, claustrum; LN, lentiform nucleus; ACC, anterior cingulate cortex; PCC, posterior cingulate cortex; SPL, superior parietal lobule; IPL, inferior parietal lobule; Pcu, precuneus.
Figure 1Brain regions with significant differences in ALFF/fALFF in meta-analysis between schizophrenia and healthy controls (P < 0.05, uncorrected, cluster size >540 mm3). The hot color represents the higher ALFF/fALFF in schizophrenia patients. The cold color represents the higher ALFF/fALFF in healthy controls. The overlapping area is marked in the pink color. Here, it represents the contradictory results between studies. The (−log10 (P)) value means the negative ten-logarithm transformation of P value. A larger value of (−log10 (P))represents a smaller P value.
Figure 2Brain regions with significant differences in ReHo in meta-analysis between schizophrenia and healthy controls (P < 0.05, uncorrected, cluster size >540 mm3). The hot color represents the higher ReHo in schizophrenia patients. The cold color represents the higher ReHo in healthy controls. The (−log10 (P)) value means the negative ten-logarithm transformation of P value. A larger value of (−log10 (P)) represents a smaller P value.
Demographic and clinical data of participants in the large-sample study.
| Variables | Patients | Controls |
|
|---|---|---|---|
| Age (years) | 33.4 ± 7.8 | 33.5 ± 10.6 | 0.957 |
| Gender (males/females) | 46/40 | 40/49 | 0.258 |
| Illness duration (months) | 16.3 ± 41.1 | — | — |
| PANSS total | 70.5 ± 23.4 | — | — |
| PANSS positive | 16.6 ± 8.1 | — | — |
| PANSS negative | 20.2 ± 8.9 | — | — |
Among the 86 schizophrenia patients, 6 patients were first-episode and 80 patients were chronic.
Figure 3Brain regions with significant differences in ALFF in validation study between schizophrenia patients and healthy controls (FDR < 0.05, two-tailed, cluster size >540 mm3). The hot color represents the higher ALFF in schizophrenia patients. The cold color represents the higher ALFF in healthy controls.
Figure 4Brain regions with significant differences in fALFF in validation study between schizophrenia patients and healthy controls (FDR < 0.05, two-tailed, cluster size >540 mm3). The hot color represents the higher fALFF in schizophrenia patients. The cold color represents the higher fALFF in healthy controls.
Figure 5Brain regions with significant differences in ReHo in validation study between schizophrenia patients and healthy controls (FDR < 0.05, two-tailed, cluster size >540 mm3). The hot color represents the higher ReHo in schizophrenia patients. The cold color represents the higher ReHo in healthy controls.